Horizon Pharma PLC (HZNP) Expected to Announce Earnings of $0.11 Per Share

Equities research analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to report earnings of $0.11 per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Horizon Pharma’s earnings, with estimates ranging from $0.06 to $0.15. Horizon Pharma posted earnings of $0.03 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 266.7%. The firm is expected to issue its next quarterly earnings report on Wednesday, May 8th.

On average, analysts expect that Horizon Pharma will report full year earnings of $1.73 per share for the current fiscal year, with EPS estimates ranging from $1.65 to $1.78. For the next financial year, analysts anticipate that the company will post earnings of $2.01 per share, with EPS estimates ranging from $1.80 to $2.16. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Horizon Pharma.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.13. Horizon Pharma had a negative net margin of 6.34% and a positive return on equity of 34.09%. The company had revenue of $355.50 million for the quarter, compared to analyst estimates of $334.22 million. During the same quarter last year, the firm posted $0.29 earnings per share. The business’s quarterly revenue was up 29.6% on a year-over-year basis.

HZNP has been the subject of a number of recent analyst reports. BidaskClub downgraded shares of Horizon Pharma from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 29th. Mizuho reissued a “hold” rating and set a $21.00 price target on shares of Horizon Pharma in a research report on Thursday, February 7th. Cowen set a $33.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Thursday, February 28th. Morgan Stanley raised shares of Horizon Pharma from an “equal weight” rating to an “overweight” rating and set a $32.00 price target for the company in a research report on Friday, March 8th. Finally, Piper Jaffray Companies set a $26.00 price target on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Monday, January 14th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Horizon Pharma has an average rating of “Buy” and an average target price of $28.09.

In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 8,835 shares of Horizon Pharma stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total value of $204,530.25. Following the completion of the transaction, the executive vice president now owns 32,202 shares of the company’s stock, valued at $745,476.30. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Geoffrey M. Curtis sold 10,080 shares of Horizon Pharma stock in a transaction on Monday, February 25th. The stock was sold at an average price of $21.21, for a total transaction of $213,796.80. Following the completion of the transaction, the executive vice president now directly owns 35,367 shares of the company’s stock, valued at approximately $750,134.07. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Horizon Pharma by 3.8% during the third quarter. Vanguard Group Inc. now owns 14,813,841 shares of the biopharmaceutical company’s stock valued at $290,055,000 after acquiring an additional 547,099 shares during the period. Vanguard Group Inc boosted its holdings in shares of Horizon Pharma by 3.8% during the third quarter. Vanguard Group Inc now owns 14,813,841 shares of the biopharmaceutical company’s stock valued at $290,055,000 after acquiring an additional 547,099 shares during the period. Scopia Capital Management LP boosted its holdings in shares of Horizon Pharma by 23.9% during the third quarter. Scopia Capital Management LP now owns 14,762,354 shares of the biopharmaceutical company’s stock valued at $289,047,000 after acquiring an additional 2,850,064 shares during the period. BlackRock Inc. boosted its holdings in shares of Horizon Pharma by 2.0% during the fourth quarter. BlackRock Inc. now owns 13,896,831 shares of the biopharmaceutical company’s stock valued at $271,544,000 after acquiring an additional 266,698 shares during the period. Finally, William Blair Investment Management LLC boosted its holdings in shares of Horizon Pharma by 6.7% during the third quarter. William Blair Investment Management LLC now owns 10,601,147 shares of the biopharmaceutical company’s stock valued at $207,570,000 after acquiring an additional 663,821 shares during the period. 88.83% of the stock is owned by hedge funds and other institutional investors.

HZNP stock opened at $27.89 on Friday. Horizon Pharma has a twelve month low of $12.55 and a twelve month high of $29.44. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.03 and a quick ratio of 1.97. The company has a market cap of $4.73 billion, a PE ratio of 15.24, a P/E/G ratio of 1.49 and a beta of 1.16.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Further Reading: The Discount Rate – What You Need to Know

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply